Plasmid DNA has long been the workhorse of cell and gene therapy supporting countless clinical programs and enabling many of the field’s most important breakthroughs. At the same time, cell‑free DNA has already reached clinical use, where it is increasingly adopted to treat patients and now operates alongside plasmid DNA within today’s manufacturing landscape.

As therapeutic complexity increases—particularly in next-generation viral vectors, gene-edited therapies, and advanced modalities—the conversation is no longer about replacement. It’s about optimization: selecting the right DNA technology to meet evolving demands for scale, consistency, speed, and cost of goods.

Join two leading DNA experts for a candid, technical debate exploring where plasmid DNA continues to excel, where cell-free DNA is uniquely positioned, and how both platforms will shape the future of the cell and gene therapy landscape.

Expect real-world data, clinical perspective, and an informed discussion on how proven DNA technologies can unlock the next phase of genetic medicine.

Featured Speakers:

• The Plasmid Corner: Pratima Cherukuri, General Manager, Vice President of pDNA Process Development from Bionova Scientific
• The Cell-Free Corner: Jill Makin, CSO from Touchlight